Adicet Bio (ACET) Common Equity (2017 - 2026)

Adicet Bio's Common Equity history runs 10 years deep, the most recent figure standing at $140.1 million for Q1 2026.

• In Q1 2026, Common Equity fell 13.24% year-over-year to $140.1 million; the TTM figure through Mar 2026 stood at $140.1 million (down 13.24% YoY), while the FY2025 annual figure was $159.2 million, down 14.68% from the prior year.
• Common Equity for Q1 2026 stood at $140.1 million, down from $159.2 million in the prior quarter.
• The five-year high for Common Equity was $317.7 million in Q3 2022, with the low at $109.1 million in Q3 2025.
• The 5-year median for Common Equity is $211.5 million (2024), against an average of $216.5 million.
• The sharpest annual moves came in 2022 and 2025: Common Equity soared 46.24% in 2022, then sank 48.4% in 2025.
• Adicet Bio's Common Equity stood at $292.3 million in 2022, then sank by 41.79% to $170.2 million in 2023, then gained by 9.66% to $186.6 million in 2024, then decreased by 14.68% to $159.2 million in 2025, then decreased by 12.02% to $140.1 million in 2026.
• Business Quant data shows ACET's Common Equity at $140.1 million in Q1 2026, $159.2 million in Q4 2025, and $109.1 million in Q3 2025.